Main Article Content
Abstract
Dyslipidemia is one of the major contributors to atherosclerosis and coronary heart disease in our society. Dyslipidemic drugs are widely used either for prophylaxis or treatment of dyslipidemia. HMG CoA reductase inhibitors (statins) are a widely used class of lipid lowering drugs, which are generally well-tolerated, with an acceptable side effect profile. They are the first line of therapy for lipid lowering and attaining ATP III goals.
The objective of the study is to determine the prescribing pattern and drug interactions of dyslipidemic agents in the selected study population as per the inclusion criteria. A prospective observational study was conducted. The data was collected during regular ward rounds and was analysed.
The prevalence of CVD was significantly higher (62%) in the study population. The majority of patients 144 (96%) were receiving lipid lowering therapy with statins and 5 (3.33%) patients were on combination therapy including a statin and fibrate and 1 (0.67%) patient was on fibrate alone. Atorvastatin is majorly prescribed in 137 (91.95%) patients followed by rosuvastatin in 12 (8.05%) patients. The drug interaction between dyslipidemic agents were analysed and categorized, there were 2 (1.55%) major, 125 (96.90%) moderate and 2 (1.55%) minor possible drug-drug interactions were found.
The results reveal that statins were prescribed more compared to other classes of dyslipidemic agents. Atorvastatin was the most commonly prescribed statin in the study site for the treatment of dyslipidemia. Atorvastatin utilization is significantly higher than rosuvastatin, even though recent studies describes that rosuvastatin is more efficacious and safe when compared to atorvastatin. Further studies may justify effectiveness of various statins.
Keywords
Article Details
References
- [1]. Goyal P, Sharma G, Baljinderpal S. Prospective, non-interventional, uncontrolled, openchart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India. ClinTher. 24(12), 2002, 2064–76.
- [2]. Sangeetha Raja, SatyajitMohapatra, Kumar J.S, Jamuna Rani R. Study On Prescription Patterns of Hypolipidaemic Drugs in a Tertiary Care Teaching Hospital of Southern India; JCDR. 8(4), 2014, HC01-HC03.
- [3]. Anju P, Pratyay P.D. Prospective, pharmacoepidemiologic study of prescribing patterns for lipid lowering drugs. Natl J Med Res. 2(4), 2012, 400-3
- [4]. Basavambika V Anandi, Vardhamane S. Rational prescription of lipid-lowering agents statin monotherapy and combination of statins with other lipid lowering agents and the treatment of dyslipidemia; JEMDS. 3(29), 2014, 8218-26.
- [5]. Amiri. M, Hazreen Abdul Majid, Prevalence and determinants of cardiovascular disease risk factors among the residents of urban community housing projects in Malaysia. BMC Public Health. 14(3), 2014, S3.
- [6]. Jean F, Elisabeth T.G, Caroline F, Michel P, Hermans. Assessment of lipid lowering treatment in France- The CEPHEUS study. ACVD. 101, 2008, 557-63.
- [7]. Sreedevi K, Venkateswara R.J. Study on prescription pattern of statins in cardiovascular disease; Scholars Research Library. 3(3), 2011, 393-6.
- [8]. Atul Kumar, Ananddev, Kumar B. Comparison of safety and efficacy of rosuvastatin and atorvastatin in cases of dyslipidemia over twelve weeks of treatment; IJAR. 6(7), 2010, 500-3.
References
[1]. Goyal P, Sharma G, Baljinderpal S. Prospective, non-interventional, uncontrolled, openchart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India. ClinTher. 24(12), 2002, 2064–76.
[2]. Sangeetha Raja, SatyajitMohapatra, Kumar J.S, Jamuna Rani R. Study On Prescription Patterns of Hypolipidaemic Drugs in a Tertiary Care Teaching Hospital of Southern India; JCDR. 8(4), 2014, HC01-HC03.
[3]. Anju P, Pratyay P.D. Prospective, pharmacoepidemiologic study of prescribing patterns for lipid lowering drugs. Natl J Med Res. 2(4), 2012, 400-3
[4]. Basavambika V Anandi, Vardhamane S. Rational prescription of lipid-lowering agents statin monotherapy and combination of statins with other lipid lowering agents and the treatment of dyslipidemia; JEMDS. 3(29), 2014, 8218-26.
[5]. Amiri. M, Hazreen Abdul Majid, Prevalence and determinants of cardiovascular disease risk factors among the residents of urban community housing projects in Malaysia. BMC Public Health. 14(3), 2014, S3.
[6]. Jean F, Elisabeth T.G, Caroline F, Michel P, Hermans. Assessment of lipid lowering treatment in France- The CEPHEUS study. ACVD. 101, 2008, 557-63.
[7]. Sreedevi K, Venkateswara R.J. Study on prescription pattern of statins in cardiovascular disease; Scholars Research Library. 3(3), 2011, 393-6.
[8]. Atul Kumar, Ananddev, Kumar B. Comparison of safety and efficacy of rosuvastatin and atorvastatin in cases of dyslipidemia over twelve weeks of treatment; IJAR. 6(7), 2010, 500-3.